IAN Alpha Fund, the 2nd in the series of IAN Group’s VC funds, along with Speciale Invest, has co-led a ₹70 crore Series A funding round in Peptris, a Bengaluru-based AI-powered drug discovery company. The round also saw participation from Tenacity Ventures, BYT Ventures, and other investors. The investment strengthens Peptris’ proposition as one of the leading Indian AI drug discovery platforms progressing beyond molecule generation towards clinical-ready assets. It is an opportune time for such an investment, as companies like Peptris not only help drug companies globally reduce development costs amid high failure rates but also assist with life-cycle management of their patents.Founded in 2019, Peptris has built an AI-led discovery engine that addresses one of the most persistent problems in healthcare: despite scientific advances, drug discovery remains slow, expensive, and failure-prone, leaving large unmet medical needs. This challenge is most acute in the pre-clinical stage, where time, capital, and scientific uncertainty often derail promising programs much before drugs reach the clinical stage.Peptris’ differentiator is its proprietary AI models, which not only generate novel molecules but also help predict critical drug development parameters early. This enables faster and better-informed decision-making and has already resulted in the discovery of Novel… Read MoreStartupTalky- Business News, Insights and Stories
